Scholarlink

Background <p>This study aims to present the Segmentation-based Myocardial Advanced Refinement Tracking (SMART) system, a novel artificial intelligence (AI)-based framework for transthoracic echocardiography (TTE) that incorporates motion tracking and left ventricular (LV) myocardial segmentation for automated LV mass (LVM) and global longitudinal strain (LVGLS) assessment.</p> Methods <p>The SMART system demonstrates LV speckle tracking based on motion vector estimation, refined by structural information using endocardial and epicardial segmentation throughout the cardiac cycle. This approach enables automated measurement of LVM<sub>SMART</sub> and LVGLS<sub>SMART</sub>. The feasibility of SMART is validated in 111 hypertrophic cardiomyopathy (HCM) patients (median age: 58&#xa0;years, 69% male) who underwent TTE and cardiac magnetic resonance imaging (CMR).</p> Results <p>LVGLS<sub>SMART</sub> showed a strong correlation with conventional manual LVGLS measurements (Pearson’s correlation coefficient [PCC] 0.851; mean difference 0 [-2–0]). When compared to CMR as the reference standard for LVM, the conventional dimension-based TTE method overestimated LVM (PCC 0.652; mean difference: 106 [90–123]), whereas LVM<sub>SMART</sub> demonstrated excellent agreement with CMR (PCC 0.843; mean difference: 1 [-11–13]). For predicting extensive myocardial fibrosis, LVGLS<sub>SMART</sub> and LVM<sub>SMART</sub> exhibited performance comparable to conventional LVGLS and CMR (AUC: 0.72 and 0.66, respectively). Patients identified as high risk for extensive fibrosis by LVGLS<sub>SMART</sub> and LVM<sub>SMART</sub> had significantly higher rates of adverse outcomes, including heart failure hospitalization, new-onset atrial fibrillation, and defibrillator implantation.</p> Conclusions <p>The SMART technique provides a comparable LVGLS evaluation and a more accurate LVM assessment than conventional TTE, with predictive values for myocardial fibrosis and adverse outcomes. These findings support its utility in HCM management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel deep learning framework for simultaneous assessment of left ventricular mass and longitudinal strain: clinical feasibility and validation in patients with hypertrophic cardiomyopathy

  • 期刊论文

  • 发表日期：

    2025年7月12日

查看全文
  • Jiesuck Park,
  • Yeonyee E. Yoon,
  • Yeonggul Jang,
  • Taekgeun Jung,
  • Jaeik Jeon,
  • Seung-Ah Lee,
  • Hong-Mi Choi,
  • In-Chang Hwang,
  • Eun Ju Chun,
  • Goo-Yeong Cho,
  • Hyuk-Jae Chang

摘要

Background

This study aims to present the Segmentation-based Myocardial Advanced Refinement Tracking (SMART) system, a novel artificial intelligence (AI)-based framework for transthoracic echocardiography (TTE) that incorporates motion tracking and left ventricular (LV) myocardial segmentation for automated LV mass (LVM) and global longitudinal strain (LVGLS) assessment.

Methods

The SMART system demonstrates LV speckle tracking based on motion vector estimation, refined by structural information using endocardial and epicardial segmentation throughout the cardiac cycle. This approach enables automated measurement of LVMSMART and LVGLSSMART. The feasibility of SMART is validated in 111 hypertrophic cardiomyopathy (HCM) patients (median age: 58 years, 69% male) who underwent TTE and cardiac magnetic resonance imaging (CMR).

Results

LVGLSSMART showed a strong correlation with conventional manual LVGLS measurements (Pearson’s correlation coefficient [PCC] 0.851; mean difference 0 [-2–0]). When compared to CMR as the reference standard for LVM, the conventional dimension-based TTE method overestimated LVM (PCC 0.652; mean difference: 106 [90–123]), whereas LVMSMART demonstrated excellent agreement with CMR (PCC 0.843; mean difference: 1 [-11–13]). For predicting extensive myocardial fibrosis, LVGLSSMART and LVMSMART exhibited performance comparable to conventional LVGLS and CMR (AUC: 0.72 and 0.66, respectively). Patients identified as high risk for extensive fibrosis by LVGLSSMART and LVMSMART had significantly higher rates of adverse outcomes, including heart failure hospitalization, new-onset atrial fibrillation, and defibrillator implantation.

Conclusions

The SMART technique provides a comparable LVGLS evaluation and a more accurate LVM assessment than conventional TTE, with predictive values for myocardial fibrosis and adverse outcomes. These findings support its utility in HCM management.